Merck's keytruda snags 5th approval in single cancer - NSCLCIf Merck (MSD) can have its 5th approval by the FDA in a single cancer (NSCLC), ask yourself how many indications ONCY's can have approved in metastatic breast cance for example. 2, 3, 4 or more? And then how many more in pancreatic cancer, and then colorectal cancer (msCRC), etc.
" A PD-1 checkpoint inhibitor, Keytruda is Merck’s top-performing asset, earning more than $15 billion in year-to-date revenue by the end of Q3, 2022. Aside from NSCLC, the drug is also approved for Hodgkin lymphoma, melanoma, colorectal cancer, cervical cancer, breast cancer and hepatocellular carcinoma, among several other indications."
https://www.biospace.com/article/merck-s-keytruda-snags-fifth-nsclc-nod/